

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BeOne Medicines Ltd.**

**百濟神州有限公司**

*(a corporation incorporated under the laws of Switzerland)*

**(Stock Code: 06160)**

## **DATE OF SECOND QUARTER 2026 FINANCIAL RESULTS ANNOUNCEMENT AND NOTICE OF AUDIT COMMITTEE ACTION**

BeOne Medicines Ltd. (the “**Company**”) hereby announces that it will report its unaudited financial results for the second quarter ended June 30, 2026 prepared in accordance with U.S. Generally Accepted Accounting Principles (the “**U.S. GAAP**”) and the applicable rules of the U.S. Securities and Exchange Commission (the “**SEC**”) on Wednesday, August 5, 2026 (after the trading hours of the Hong Kong Stock Exchange). The second quarter 2026 financial results will be reviewed and approved by the audit committee of the board of directors of the Company on August 5, 2026 (Hong Kong Time).

Following the release of the financials, the Company will host a conference call with the Company’s management at 8:00 a.m. U.S. Eastern Time on Wednesday, August 5, 2026 (8:00 p.m. Hong Kong Time on Wednesday, August 5, 2026).

The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company’s website at <https://ir.beonemedicines.com>. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website.

The Company will further issue an announcement of its interim results for the six months ended June 30, 2026 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) on or before August 31, 2026, which are expected to be the same as the interim results prepared in accordance with U.S. GAAP and the applicable rules of the SEC, except for specific additional information required by the HK Listing Rules, together with a reconciliation of the Company’s interim results from U.S. GAAP to International Financial Reporting Standards.

By order of the Board  
**BeOne Medicines Ltd.**  
**Mr. John V. Oyler**  
*Chairman*

Hong Kong, July 17, 2026

*As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Felix J. Baker and Dr. Xiaodong Wang as Non-executive Directors, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp as Independent Non-executive Directors.*